Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2026-03-09 @ 4:05 AM
Study NCT ID:
NCT01861834
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2019-05-07
First Post:
2013-05-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006963', 'term': 'Hyperphagia'}, {'id': 'D000090124', 'term': 'Intestinal Failure'}, {'id': 'D012778', 'term': 'Short Bowel Syndrome'}, {'id': 'D002779', 'term': 'Cholestasis'}], 'ancestors': [{'id': 'D012817', 'term': 'Signs and Symptoms, Digestive'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008286', 'term': 'Malabsorption Syndromes'}, {'id': 'D011183', 'term': 'Postoperative Complications'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D001649', 'term': 'Bile Duct Diseases'}, {'id': 'D001660', 'term': 'Biliary Tract Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'EXPANDED_ACCESS'}, 'statusModule': {'overallStatus': 'APPROVED_FOR_MARKETING', 'statusVerifiedDate': '2019-05', 'lastUpdateSubmitDate': '2019-05-05', 'studyFirstSubmitDate': '2013-05-22', 'studyFirstSubmitQcDate': '2013-05-22', 'lastUpdatePostDateStruct': {'date': '2019-05-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-05-24', 'type': 'ESTIMATED'}}, 'conditionsModule': {'keywords': ['Total parenteral nutrition', 'TPN', 'Intestinal Failure', 'Short Bowel Syndrome', 'Cholestasis', 'Intestinal failure associated liver disease', 'Parenteral nutrition associated liver disease'], 'conditions': ['Cholestasis of Parenteral Nutrition']}, 'descriptionModule': {'briefSummary': 'To provide children dependent on total parenteral nutrition with Omegaven®, a fish oil-based intravenous lipid emulsion that may be less hepatotoxic than conventional, vegetable oil-based intravenous lipid emulsions, and that may therefore reduce the need for liver transplantation.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '18 Years', 'minimumAge': '2 Months', 'eligibilityCriteria': 'Inclusion Criteria:\n\n* The targeted population for enrollment is the cohort of patients with TPN-dependent short bowel syndrome, defined as any pediatric patient who, following abdominal surgery, has a residual small bowel length less than 25% of that predicted for gestational age or requires postoperative TPN for more than 42 days because of gastrointestinal intolerance and who has developed TPN-associated liver disease sufficient to pose a significant risk for progression to liver failure based on the following criteria:\n\n * Total serum bilirubin concentration greater than 3 mg/dL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.\n\nPLUS EITHER:\n\n• Platelet count less than 200,000/μL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.\n\nOR\n\n• Serum albumin concentration less than 3.2 mg/dL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.\n\nPatients with coagulopathy due to parenteral nutrition-associated liver disease (INR \\> 1.2) will be potential candidates for enrollment, because patients with an elevated INR exceeding 2 have demonstrated resolution of coagulopathy after treatment with Omegaven®. Similarly, patients with hyperlipidemia will be potential candidates for enrollment.\n\nAlternatively, patients currently receiving Omegaven that was initiated at another center because of intestinal failure with liver disease that do not need to meet the lab criteria listed above. The subject may continue Omegaven under this protocol at the discretion of the Principle Investigator.\n\nExclusion Criteria:\n\nPatients with a history of the following will be excluded from enrollment in this protocol:\n\n* Allergy to fish or egg protein.\n* Liver disease proven or suspected to be caused by a process other than TPN-dependent short bowel syndrome, including but not limited to hepatitis C, hepatitis B, cystic fibrosis, biliary atresia, Alagille syndrome, familial intrahepatic cholestasis, and alpha-1-antitrypsin deficiency.\n* Refusal of third party providers to reimburse hospital for the cost of Omegaven®.'}, 'identificationModule': {'nctId': 'NCT01861834', 'briefTitle': 'Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage', 'organization': {'class': 'OTHER', 'fullName': 'Georgetown University'}, 'officialTitle': 'A Safer Approach to Total Parenteral Nutrition in Pediatric Short Bowel Syndrome Intended to Decrease the Frequency and Severity of Liver Damage', 'orgStudyIdInfo': {'id': 'IND107300'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Omegaven 10%', 'type': 'DRUG', 'description': 'Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.\n\nOmegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN'}]}, 'contactsLocationsModule': {'locations': [{'zip': '20007', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'MedStar Georgetown Transplant Institute', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '20007', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'MedStar Georgetown University Hospital', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Georgetown University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}